| Authors: |
Chen X; Clinical Pharmacology Modeling and Simulation, GSK, 1250 S. Collegeville Rd, Collegeville, PA 19426, USA., Hakim S; Oncology Clinical Development, GSK, Upper Providence, PA., Lien YTK; Clinical Pharmacology Modeling and Simulation, GSK, Waltham, MA., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea., Lichtman EI; Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC., Min CK; Department of Internal Medicine, College of Medicine, Division of Hematology, Seoul St. Mary's Hospital, Seoul, South Korea., Chng WJ; Department of Medical-Oncology, National University of Singapore, Singapore, Singapore., Ailawadhi S; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL., Delimpasi S; Hematology/Lymphomas and BMT Unit, General Hospital Evangelismos, Athens, Greece., Hrabrick E; Oncology Clinical Development, GSK, Upper Providence, PA., Papathanasiou T; Clinical Pharmacology, Modeling and Simulation, GSK, Baar, Switzerland., Ghanta SR; Oncology Clinical Development, GSK, Upper Providence, PA., McKeown A; Oncology Clinical Development, GSK, Stevenage, UK., Ferron-Brady G; Clinical Pharmacology Modeling and Simulation, GSK, 1250 S. Collegeville Rd, Collegeville, PA 19426, USA. Electronic address: geraldine.x.ferron@gsk.com. |
